The number of enrollments in the EURECA study is steadily growing, reaching a number of 406 enrolled patients this month!

There have been 31 sites initiated in 9 different countries: 1 from Albania, 1 from Croatia, 1 from Kosovo, 1 from Montenegro, 3 from Greece, 5 from Turkey, 5 from Serbia, 7 from Romania and 7 from Spain.

February’s top enrolling sites are:

  • Clinical Center of Serbia (Dr. Biljana Carevic), Belgrade; 89 patients
  • Hospital Universitario de Reina Sofia (Dr. De la Torre Cisneros), Spain; 68 patients
  • Hospital Universitari de Bellvitge (Dr. Evelyn Shaw), Barcelona, Spain; 45 patients
  • Institute of Public Health of Vojvodina (Dr. Gorana Dragovac), Serbia; 43 patients
  • Zvezdara University Medical Center (Dr. Lili Radulovic), Serbia; 32 patients
  • Hospital Universitario Carlos Haya (Dr. Colmenero), Spain; 24 patients

From all countries, there are 111 CRE (Carbapenem Resistance Enterobacteriaceae) cases, 56 CSE (infections due to Carbapenem susceptible Entertobacteriaceae) controls, 152 ADM (without infection due to Enterobacteriaceae) controls, and 87 CRAB (bloodstream infections due to carbapenem-resistant A. baumannii) cases.

All training sessions for participating sites have been done and completed by webcast; a recorded session will be also available for all participants in case they need a refresh some aspects. One more session is currently being planned for investigators who could not attend any previous ones. This will take place when pending sites will be close to finish the latest steps for activation.

EURECA (EUropean prospective cohort study on Enterobacteriaeae Showing REsistance to CArbapenems), is a prospective observational study on cohorts of patients with serious carbapenem-resistant Gram-negative bacterial infections. The study aims to recruit a total of 2000 patients.

EURECA will lead the way towards better management of patients with complicated intra-abdominal infections (cIAI), healthcare-associated pneumonia (HCAP), complicated urinary tract infections (cUTI), and bloodstream infections (BSI). All due to carbapenem-resistant Enterobacteriaceae (CRE) and Acinetobacter baumannii (CRAB).